✦ LIBER ✦

Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases

✍ Scribed by Eliezer Masliah; Lawrence A. Hansen; Edward Rockenstein; Makoto Hashimoto

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 276 KB
Volume: 56
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.10082

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progress in understanding the pathophysi

Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease

✍ G. Frederick Wooten 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

ChemInform Abstract: Discovery and Devel

ChemInform Abstract: Discovery and Development of Donepezil Hydrochloride for the Treatment of Alzheimer′s Disease

✍ Hachiro Sugimoto; Yoshiharu Yamanishi; Hiroo Ogura; Youichi Iimura; Kiyomi Yamat 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 24 KB 👁 1 views

ChemInform Abstract: Discovery and Devel

ChemInform Abstract: Discovery and Development of Donepezil Hydrochloride for Treatment of Alzheimer′s Disease

✍ H. SUGIMOTO 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 25 KB 👁 1 views

Quetiapine for the treatment of drug-ind

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

✍ Hubert H. Fernandez; Joseph H. Friedman; Carol Jacques; Michael Rosenfeld 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 25 KB 👁 2 views

Medicinal Chemistry Approaches for the T

Medicinal Chemistry Approaches for the Treatment and Prevention of Alzheimer′s Disease

✍ S. O. Bachurin 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 50 KB 👁 1 views

The economic consequences of Alzheimer's

The economic consequences of Alzheimer's disease in the context of new drug developments

✍ Martin Knapp; David Wilkinson; Rachel Wigglesworth 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

The first national symptomatic treatment for Alzheimer's disease has received a very mixed and perhaps ageist reception from purchasers of health care in the UK. This is largely because detailed information on the long-term effects of this class of drugs is scarce. However, by looking at the publish